# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $25 ...
Jefferies analyst Akash Tewari initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price ...
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating ...
Wedbush analyst Robert Driscoll initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Outperform rating and announce...